vs
Side-by-side financial comparison of Ranpak Holdings Corp. (PACK) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Ranpak Holdings Corp. is the larger business by last-quarter revenue ($93.7M vs $57.3M, roughly 1.6× RHYTHM PHARMACEUTICALS, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 2.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 13.7%).
Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
PACK vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.7M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | 39.0% | 91.6% |
| Operating Margin | -1.0% | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | 2.3% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $-0.11 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.7M | $57.3M | ||
| Q3 25 | $83.6M | $51.3M | ||
| Q2 25 | $77.8M | $48.5M | ||
| Q1 25 | $77.6M | $32.7M | ||
| Q4 24 | $91.6M | $41.8M | ||
| Q3 24 | $78.6M | $33.3M | ||
| Q2 24 | $72.8M | $29.1M | ||
| Q1 24 | $72.5M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-10.4M | $-52.9M | ||
| Q2 25 | $-7.5M | $-46.6M | ||
| Q1 25 | $-10.9M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-8.1M | $-43.6M | ||
| Q2 24 | $5.5M | $-32.3M | ||
| Q1 24 | $-8.1M | $-141.4M |
| Q4 25 | 39.0% | 91.6% | ||
| Q3 25 | 41.1% | 89.3% | ||
| Q2 25 | 37.1% | 88.6% | ||
| Q1 25 | 39.8% | 88.8% | ||
| Q4 24 | 45.2% | 90.9% | ||
| Q3 24 | 43.8% | 88.5% | ||
| Q2 24 | 43.5% | 89.9% | ||
| Q1 24 | 44.6% | 89.2% |
| Q4 25 | -1.0% | -82.2% | ||
| Q3 25 | -6.8% | -102.6% | ||
| Q2 25 | -12.5% | -93.4% | ||
| Q1 25 | -10.3% | -143.7% | ||
| Q4 24 | 1.5% | -98.6% | ||
| Q3 24 | -5.3% | -132.0% | ||
| Q2 24 | -7.1% | -139.2% | ||
| Q1 24 | -6.6% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -12.4% | -103.1% | ||
| Q2 25 | -9.6% | -96.1% | ||
| Q1 25 | -14.0% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -10.3% | -131.2% | ||
| Q2 24 | 7.6% | -110.9% | ||
| Q1 24 | -11.2% | -544.4% |
| Q4 25 | $-0.11 | $-0.73 | ||
| Q3 25 | $-0.12 | $-0.82 | ||
| Q2 25 | $-0.09 | $-0.75 | ||
| Q1 25 | $-0.13 | $-0.81 | ||
| Q4 24 | $-0.13 | $-0.71 | ||
| Q3 24 | $-0.10 | $-0.73 | ||
| Q2 24 | $0.07 | $-0.55 | ||
| Q1 24 | $-0.10 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $388.9M |
| Total DebtLower is stronger | $401.9M | — |
| Stockholders' EquityBook value | $534.9M | $139.1M |
| Total Assets | $1.1B | $480.2M |
| Debt / EquityLower = less leverage | 0.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $388.9M | ||
| Q3 25 | $49.9M | $416.1M | ||
| Q2 25 | $49.2M | $291.0M | ||
| Q1 25 | $65.5M | $314.5M | ||
| Q4 24 | $76.1M | $320.6M | ||
| Q3 24 | $69.5M | $298.4M | ||
| Q2 24 | $65.1M | $319.1M | ||
| Q1 24 | $55.1M | $201.2M |
| Q4 25 | $401.9M | — | ||
| Q3 25 | $403.1M | — | ||
| Q2 25 | $403.1M | — | ||
| Q1 25 | $405.2M | — | ||
| Q4 24 | $406.4M | — | ||
| Q3 24 | $403.2M | — | ||
| Q2 24 | $396.1M | — | ||
| Q1 24 | $396.7M | — |
| Q4 25 | $534.9M | $139.1M | ||
| Q3 25 | $537.8M | $148.8M | ||
| Q2 25 | $539.0M | $-11.9M | ||
| Q1 25 | $544.1M | $18.9M | ||
| Q4 24 | $548.1M | $21.7M | ||
| Q3 24 | $564.3M | $11.2M | ||
| Q2 24 | $566.2M | $39.3M | ||
| Q1 24 | $560.0M | $61.6M |
| Q4 25 | $1.1B | $480.2M | ||
| Q3 25 | $1.1B | $506.9M | ||
| Q2 25 | $1.1B | $372.7M | ||
| Q1 25 | $1.1B | $386.7M | ||
| Q4 24 | $1.1B | $392.3M | ||
| Q3 24 | $1.1B | $363.6M | ||
| Q2 24 | $1.1B | $381.8M | ||
| Q1 24 | $1.1B | $258.7M |
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.75× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.71× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.5M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.5M | $-25.4M | ||
| Q3 25 | $8.5M | $-26.6M | ||
| Q2 25 | $-3.6M | $-23.3M | ||
| Q1 25 | $-1.3M | $-40.4M | ||
| Q4 24 | $6.5M | $-18.8M | ||
| Q3 24 | $10.1M | $-25.2M | ||
| Q2 24 | $19.6M | $-29.1M | ||
| Q1 24 | $5.2M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.56× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
RYTM
Segment breakdown not available.
